In vivo effects of zoledronic acid on oral mucosal epithelial cells

Oral Diseases

Volumn 17, Issue 3, 2011, Pages 291-297

  Allam, E ^a   Allen, M R ^b   Chu, T M ^a   Ghoneima, A ^a   Jack Windsor, L ^a  

^a INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Oral epithelial cells; Osteonecrosis of the jaws; Zoledronic acid

Indexed keywords

CASPASE 3; CYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUTH MUCOSA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CASPASE 3; CELL PROLIFERATION; DIPHOSPHONATES; DOGS; EPITHELIAL CELLS; FEMALE; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INJECTIONS, INTRAVENOUS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MODELS, ANIMAL; MOUTH MUCOSA; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 79952576447     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01739.x     Document Type: Article

References (45)

1. Allen MR, Burr DB (2009). The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67: 61-70.
2. Allen MR, Kubek DJ, Burr DB, Ruggiero SL, Chu TG (2010). Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int doi: .
3. Benford HL, McGowan NWA, Helfrich MH (2001). Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28: 465-473.
4. Birkedal-Hansen EL (1993). Role of matrix rnetalloproteinases in human periodontal diseases. J Periodontol 64: 474-484.
5. Bulut S, Uslu H, Özdemir B, Bulut O (2006). Expression of caspase-3, p53 and Bcl-2 in generalized aggressive periodontitis. Head Face Med 2: 17.
6. Cohen JJ (1991). Programmed cell death in the immune system. Adv Immunol 50: 55-58.
7. Cornish J, Bava U, Reid I (2009). Bisphosphonate-treated bone is toxic to epithelial cells-mechanism of ONJ?. Bone 44: S283-S283.
8. Correia VDP, Caldeira CL, Marques MM (2006). Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dental Traumatol 22: 312-317.
9. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA (2003). Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199: 221-228.
10. Fernandez-Patron C, Martinez-Cuesta MA, Salas E et al (1999). Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82: 1730-1735.
11. Fournier P, Boissier S, Filleur S et al (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
12. Giraudo E, Inoue M, Hanahan D (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633.
13. Green JR (2004). Bisphosphonates: preclinical review. The Oncologist 9: 3-13.
14. Green JR, Rogers MJ (2002). Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 55: 210-224.
15. Heikkil P, Teronen O, Moilanen M et al (2002). Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13: 245-254.
16. Hejun Y, Qin A (2009). Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas? Med Hypothesis 73: 495-497.
17. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005). The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101-111.
18. Ishikawa C, Matsuda T, Okudaira T et al (2007). Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 136: 424-432.
19. Krajewska M, Wang HG, Krajewski S et al (1997). Immunohistochemical analysis of in vivo patterens of expression of CPP32 (caspase-3), a cell death protease. Cancer Res 57: 1605-1613.
20. Landesberg R, Cozin M, Cremers S et al (2008). Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847.
21. Madlener M (1998). Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds. Arch Dermatol Res 290: S24-S29.
22. Misung J, Thomas LE, Wheeler SE, Curry TE Jr (2004). Membrane type 1-matrix metalloproteinase (MMP)-associated MMP-2 activation increases in the rat ovary in response to an ovulatory dose of human chorionic gonadotropin. Biol Reprod 70: 1024-1032.
23. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003). Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246-252.
24. Opdenakker G, Van den Steen PE, Van Damme J (2001). Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 22: 571-579.
25. Pardo A, Selman M (2006). Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 3: 383-388.
26. Paunesku T, Mittal S, Protic M et al (2001). Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 77: 1007-1021.
27. Ravanti L, Kahari V (2000). Matrix metalloproteinases in wound repair (review). Int J Mol Med 6: 391-407.
28. Reid IR (2009). Osteonecrosis of the jaw - who gets it, and why? Bone 44: 4-10.
29. Reid IR, Bolland MJ, Grey AB (2007). Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41: 318-320.
30. Ruggiero SL (2007). Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab 4: 37-42.
31. Salo T, Mäkelä M, Kylmäniemi M, Autio-Harmainen H, Larjava H (1994). Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 70: 176-182.
32. Santoro M, Gaudino G (2005). Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 304: 274-286.
33. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009). Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144: 667-676.
34. Senaratne SG, Colston KW (2002). Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4: 18-23.
35. Senaratne SG, Pirianov G, Mansi JL (2000). Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468.
36. Senaratne SG, Mansi JL, Colston KW (2002). The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86: 1479-1486.
37. Shipman CM, Rogers MJ, Apperley JF (1997). Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 98: 665-672.
38. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009). Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45: 164-172.
39. Tassone P, Tagliaferri P, Viscomi C (2003). Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978.
40. Teronen O, Heikkilä P, Konttinen YT et al (1999). MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 30: 453-465.
41. Vu TH, Shipley JM, Bergers G et al (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422.
42. Wessel JH, Dodson TB, Zavras AI (2008). Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66: 625-631.
43. Woo SB, Hellstein JW, Kalmar JR (2006). Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753-761.
44. Yu Q, Stamenkovic I (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176.
45. Zecchin KG, Pereira MC, Coletta RD, Graner E, Jorge J (2005). Ovariectomy reduces the gelatinolytic activity and expression of matrix metalloproteinases and collagen in rat molar extraction wounds. Calcif Tissue Int 76: 136-145.